ClinicalTrials.gg
Not yet recruitingNCT07942272DETECSEPSUpdated Nov 17, 2026

Early Sepsis Detection Using NEWS2 and Circulating H3.1 Nucleosomes in Emergency Departments

An interventional study of Plasma H3.1 concentration and NEWS2 score in Sepsis, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 5 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris — 14 open to participants now, 15 under way, 3 of them phase 3. Sepsis · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
4th of 23
1,000 · median 340
Started
2026
with 6 others
No phase
14 of 35
5 open now
Primary completion
2027-12
later than 7 of 14 live
Registered
35th of 35
by date

Among the 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris, this one is the 4th largest by planned enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2026, is one of 14 with no phase, reaches primary completion later than 7 of the 14 other live ones, and was the 35th registered.

Sepsis

2,418 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

14 of the 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 319 Sepsis studies recruiting now, 213 (67%) set no upper age limit and 53 (17%) stop at 75 or younger; 68 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Sepsis by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

DETECSEPS is a multicentre, randomized, open-label trial sponsored by Assistance Publique - Hôpitaux de Paris, under the scientific leadership of IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center, led by Professor Djillali Annane.

The study evaluates whether an early sepsis detection strategy combining the National Early Warning Score 2 (NEWS2) and circulating H3.1 nucleosome concentrations improves care pathways compared with usual care in adults presenting to emergency departments with suspected or confirmed infection and at least one risk factor for sepsis.

The strategy aims to support timely recognition and management of sepsis and to identify patients suitable for discharge with ambulatory follow-up when hospital admission is not otherwise indicated. The study will assess care pathway optimization at 24 hours, clinical outcomes, health-related quality of life, return to usual activities, and economic and environmental outcomes.

Read the detailed description

DETECSEPS will enrol 1,000 adults across participating emergency departments. Participants will be randomized to either a diagnostic and management strategy guided by NEWS2 and circulating H3.1 nucleosome concentrations or usual care.

In the intervention group, the combined algorithm will guide clinical management and disposition according to the approved study protocol. The description of the algorithm will specify the actions associated with each combination of NEWS2 and H3.1 categories, including discharge with ambulatory follow-up, hospital admission, early sepsis management, and assessment for intensive care admission.

In the usual-care group, management will follow routine clinical practice. Research H3.1 results will not be disclosed to treating clinicians. The record will distinguish any NEWS2 score calculated specifically for research from physiological measurements and assessment tools available during routine care.

The primary outcome is the proportion of participants with an optimized care pathway at 24 hours. Participants will be followed for six months.

IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center is responsible for the scientific leadership of the study. Assistance Publique - Hôpitaux de Paris is the study sponsor.

03

Conditions studied

  • Sepsis

Browse trials for

Keywords

  • Sepsis
  • Early diagnostic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All genders patients
  2. Aged of 18 years or older
  3. Proven or suspected infection
  4. At least one risk factor for sepsis (cf HAS recommendations) :

    • Age/frailty : >65 year; Clinical Frailty Scale ≥5; postpartum; Cognitive or motor disabilities; Implantable medical device; Recent surgery
    • Inborn immune deficit
    • Acquired immune deficit :

      • Diseases related : Cancer, Transplant patient, Chronic inflammatory or disease, , Asplenic anatomical or functional (Sickle cell disease)
      • Treatment related : Long-term corticotherapy, chemotherapy, Biotherapy, Cell therapy, radiotherapy, drugs,
    • Non immune disorders : Cirrhosis, chronic liver disease, chronic renal insufficiency, chronic cardiac failure, diabetes with complication or uncontrolled, malnutrition, previous episode of sepsis

Exclusion criteria

Exclusion Criteria:

  1. Refused to consent participating in the study,
  2. Any condition for which patient's primary physician will consider inappropriate enrolling patient in the study,
  3. Previous enrolment
  4. Pregnancy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    NEWS2 and H3.1-guided diagnostic and management strategy

    Clinical management and disposition will be guided by a prespecified algorithm combining NEWS2 and circulating H3.1 nucleosome concentrations. Decisions will follow the thresholds and management rules specified in the protocol. Upon randomization, NEWS2 score and plasma level of H3.1 will be provided to the investigator and healthcare staff to guide management as per decision tree below : * If NEWS2 ≤2 AND H3.1 ≤50 ng/ml, the progression to sepsis is very unlikely or unlikely and the patient can be discharged home with ambulatory follow-up via teleconsultation. * If NEWS2 ≥5 and H3.1 ≥740 ng/ml, the progression to sepsis is likely or very likely and the 3-hour bundle of the Surviving Sepsis Campaign will be implemented and admission to the ICU within 6 hours of arrival at Emergency Department is required. * In any other case, patients will be monitored in the emergency department and NEWS 2 and plasma H3.1 level are recorded again at 3 hours.

    Other: Plasma H3.1 concentration · Other: NEWS2 score

  • Other
    Usual care

    Comparator arm description: Participants will receive usual diagnostic assessment and clinical management. H3.1 nucleosome concentrations will be measured for research purposes, but results will not be disclosed to treating clinicians.

    Other: Plasma H3.1 concentration · Other: NEWS2 score

Interventions

  • OtherPlasma H3.1 concentration

    This biomarker levels will be measured with Nu.Q® NETs/H3.1 automated system. The result will not be disclosed to the investigators and healthcare staff in the control arm

  • OtherNEWS2 score

    The NEWS is based on a simple aggregate scoring system in which a score is allocated to physiological measurements, already recorded in routine practice, when patients present to, or are being monitored in hospital. Six simple physiological parameters form the basis of the scoring system: 1. respiration rate 2. oxygen saturation 3. systolic blood pressure 4. pulse rate 5. level of consciousness or new confusion 6. temperature The result will not be disclosed to the investigators and healthcare staff in the control arm

06

What researchers measure

Primary outcomes

  1. Proportion of patients with optimized care pathway

    The best care pathway is defined by: discharge to home in the absence of confirmed sepsis, or hospitalization whenever any other reason than sepsis will mandate hospital admission If sepsis is confirmed: * Implementation of good clinical practice recommendations within 3 hours of arrival at ED (3-hour bundle of the Surviving Sepsis Campaign \& HAS recommendations) * ICU admission within 6 hours of arrival at ED

    Time frame: 24 hours after inclusion

Secondary outcomes

  1. Death rate

    Time frame: At 6 months

  2. Cumulative incidence of direct ICU admission

    Time frame: Up to 6 months

  3. Cumulative incidence of secondary ICU admission

    ie after admission to ward

    Time frame: Up to 6 months

  4. Proportion of patients with cognitive, psychological, or physical sequelae

    Time frame: Up to 6 months

  5. Proportion of patients requiring renal, respiratory, or cardiovascular support

    Organ support is defined as needing either respiratory, cardiovascular or renal support. Respiratory support is defined as high flow oxygen, non-invasive or invasive ventilation, extracorporeal membrane oxygenation or CO2 removal. Cardiovascular support is defined as ongoing infusion of any dose of any vasopressor or inotrope drug, or mechanical circulatory assistance. Renal support is defined by the requirement of renal replacement therapy regardless of treatment modalities. We will also compute the number of days free of organ support up to 7 and 28 days, with higher score indicating faster recovery

    Time frame: Up to day 7

  6. Proportion of patients requiring renal, respiratory, or cardiovascular support

    Organ support is defined as needing either respiratory, cardiovascular or renal support. Respiratory support is defined as high flow oxygen, non-invasive or invasive ventilation, extracorporeal membrane oxygenation or CO2 removal. Cardiovascular support is defined as ongoing infusion of any dose of any vasopressor or inotrope drug, or mechanical circulatory assistance. Renal support is defined by the requirement of renal replacement therapy regardless of treatment modalities. We will also compute the number of days free of organ support up to 7 and 28 days, with higher score indicating faster recovery

    Time frame: Up to day 28

  7. Time to discharge to home

    Time frame: Up to 6 months

  8. Time to resume previous social and professional activities

    Time frame: Up to 6 months

  9. Quality of life - EQ-5D-5L

    The EQ-5D-5L is a patient-reported questionnaire assessing health-related quality of life across five dimensions, with higher index and EQ VAS scores indicating better health status

    Time frame: At 6 months

  10. Quality of life - SF36

    The SF-36 is a 36-item patient-reported questionnaire assessing health-related quality of life across eight physical and mental health domains, with higher scores indicating better health status and functioning.

    Time frame: At 6 months

  11. Cost of strategies and care pathways

    Costs of strategies and care pathways at 6 months with and without early H3.1 concentrations and the NEWS2 clinical score, incremental cost-effectiveness ratio calculated by the ratio of the difference in costs to the difference in survival without sequelae and without organ failure at 6 months.

    Time frame: At 6 months

  12. Proportion of cases for which the combined diagnostic protocol is applied as intended

    e.g., correct use of NEWS2 and H3.1 nucleosome testing

    Time frame: Up to 6 months

  13. Proportion of test results available below a meaningful clinical duration to allow for patient management.

    Time frame: Up to 6 months

  14. Proportion of appropriate integration of tests results within clinical workflow

    Time frame: Up to 6 months

  15. Proportion of avoided hospitalization among patients receiving the intervention

    Time frame: Up to 6 months

  16. Evolution of the proportion of eligible patients included over time

    Time frame: Up to 6 months

  17. Environmental impact of study-related procedures

    The environmental footprint of each component of the research process will be assess, including: * Biological sampling: Biomarkers will be measured from routine care tubes, avoiding the use of dedicated research tubes, which often expire unused and contribute to waste. * Patient transport: No additional on-site visits will be required for the study, limiting travel-related emissions (Lyle et al., BMJ, 2009). * Study documentation: Digital consent forms (e-consent) will be preferred. When choosing between paper or electronic formats, the environmental impact of printing, document replacement after amendments, and digital storage will be considered. All study procedures will be reviewed according to the guidance proposed by Griffiths et al. (BMJ Open, 2024), which identified high-impact areas in clinical trials. The goal is to apply these recommendations throughout the study.

    Time frame: Up to 6 months

  18. Life cycle analyse (LCA)

    Life cycle analyses (LCA) of the new algorithm and its associated device. It will be based on the Life Cycle Assessment (LCA) framework proposed by Ashby (Materials and the Environment, 2013), using Granta EduPack® software tools.

    Time frame: Up to 6 months

  19. LCA comparison of the two clinical strategies

    The two clinical strategies will be compared using LCA to assess their respective environmental impacts from patient inclusion to the end of follow-up. This approach is inspired by previous work (Makhloufi et al., Nephrol Dial Transplant, 2024), integrating medical and ecological outcomes. The average carbon emissions and water consumption between the two groups will be compared by collecting all activities from the time of inclusion until the end of follow-up in the study.

    Time frame: Up to 6 months

Other outcomes

  1. Circulating levels of C-reactive protein, procalcitonin, NETs, neutrophil degranulation markers, cytokines and chemokines

    Time frame: At baseline, day 1 and day 7

  2. Multi-omic profile

    Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

    Time frame: At baseline

  3. Multi-omic profile

    Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

    Time frame: At day 1

  4. Multi-omic profile

    Characterization of blood transcriptomic (RNA expression), proteomic (protein abundance) and metabolomic (metabolite abundance) profiles, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis. No DNA analyses will be performed.

    Time frame: At day 7

  5. Innate immune cells activation markers and sub-populations

    Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

    Time frame: At baseline

  6. Innate immune cells activation markers and sub-populations

    Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

    Time frame: At day 1

  7. Innate immune cells activation markers and sub-populations

    Characterization of peripheral blood innate immune cell subpopulation frequencies and activation-marker expression, including their changes over time and associations with circulating H3.1 concentrations and progression to sepsis.

    Time frame: At day 7

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: Yes — According to DETECSEPS consortium data management plan, upon request to IHU SEPSIS and to APHP

Time frame: Within 6 months from publication of the study results

Access criteria: Upon request to IHU SEPSIS and to APHP according to the data management plan of the Consortium

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 301 non-industry interventional studies with no phase under Sepsis, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 12 months is below that.

Counting every sponsor, half of 324 studies reached it within 22 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 2, 2027
CompletionEst.
Jun 1, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942272
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 2, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Djillali Annane
Contact
djillali.annane@aphp.fr
+33 1 47 10 77 87 ext. +33
Sébastien Beaune, MD PhD
Contact
sebastien.beaune@aphp.fr
+33 1 49 09 46 56 ext. +33
Djillali Annane, MD PhD
study chair · IHU SEPSIS - PROMETHEUS Comprehensive Sepsis Center, AP-HP, Université Paris-Saclay

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion